AR027484A1 - USEFUL FUSION PROTEIN IN THE TREATMENT OR PREVENTION OF ZOSTER HERPES AND IN THE PREVENTION OR TREATMENT OF VARICEL, DNA AND RNA INFECTIONS QUECODIFY SUCH PROTEIN; EXPRESSION VECTORS AND RECOMBINANT MICROORGANISMS THAT INCLUDE SUCH DNA OR RNA; VACCINE COMPOSITIONS THAT INCLUDE DICH - Google Patents

USEFUL FUSION PROTEIN IN THE TREATMENT OR PREVENTION OF ZOSTER HERPES AND IN THE PREVENTION OR TREATMENT OF VARICEL, DNA AND RNA INFECTIONS QUECODIFY SUCH PROTEIN; EXPRESSION VECTORS AND RECOMBINANT MICROORGANISMS THAT INCLUDE SUCH DNA OR RNA; VACCINE COMPOSITIONS THAT INCLUDE DICH

Info

Publication number
AR027484A1
AR027484A1 ARP000100224A ARP000100224A AR027484A1 AR 027484 A1 AR027484 A1 AR 027484A1 AR P000100224 A ARP000100224 A AR P000100224A AR P000100224 A ARP000100224 A AR P000100224A AR 027484 A1 AR027484 A1 AR 027484A1
Authority
AR
Argentina
Prior art keywords
rna
dna
treatment
prevention
protein
Prior art date
Application number
ARP000100224A
Other languages
Spanish (es)
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of AR027484A1 publication Critical patent/AR027484A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una proteína de fusion que comprende (1) una proteína gE del virus de la varicela Zoster o un fragmento inmunologicamente activo de la misma fusionados a(2) una proteína diferente del virus de la Varicela Zoster o un fragmento inmunologicamente activ o de la misma. También se propone el ADN y/o ARN y vectoresrecombinantes que codifican dicha proteína y composiciones de vacuna formuladas con dichas proteínas de aplicacion para el tratamiento de pacientes afectados osusceptibles de ser afectados po r infecciones o recurrencias del virus de la varicela zoster.A fusion protein comprising (1) a varicella Zoster virus gE protein or an immunologically active fragment thereof fused to (2) a different protein from Varicella Zoster virus or an immunologically active fragment thereof. It is also proposed the DNA and / or RNA and recombinant vectors encoding said protein and vaccine compositions formulated with said application proteins for the treatment of patients affected or susceptible to being affected by infections or recurrences of the varicella zoster virus.

ARP000100224A 1999-01-20 2000-01-18 USEFUL FUSION PROTEIN IN THE TREATMENT OR PREVENTION OF ZOSTER HERPES AND IN THE PREVENTION OR TREATMENT OF VARICEL, DNA AND RNA INFECTIONS QUECODIFY SUCH PROTEIN; EXPRESSION VECTORS AND RECOMBINANT MICROORGANISMS THAT INCLUDE SUCH DNA OR RNA; VACCINE COMPOSITIONS THAT INCLUDE DICH AR027484A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9901254.4A GB9901254D0 (en) 1999-01-20 1999-01-20 Vaccines

Publications (1)

Publication Number Publication Date
AR027484A1 true AR027484A1 (en) 2003-04-02

Family

ID=10846213

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100224A AR027484A1 (en) 1999-01-20 2000-01-18 USEFUL FUSION PROTEIN IN THE TREATMENT OR PREVENTION OF ZOSTER HERPES AND IN THE PREVENTION OR TREATMENT OF VARICEL, DNA AND RNA INFECTIONS QUECODIFY SUCH PROTEIN; EXPRESSION VECTORS AND RECOMBINANT MICROORGANISMS THAT INCLUDE SUCH DNA OR RNA; VACCINE COMPOSITIONS THAT INCLUDE DICH

Country Status (5)

Country Link
AR (1) AR027484A1 (en)
AU (1) AU2292600A (en)
CO (1) CO5241364A1 (en)
GB (1) GB9901254D0 (en)
WO (1) WO2000043527A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
AU2012213948B2 (en) * 2005-03-03 2016-01-21 Glaxosmithkline Biologicals S.A. Vaccine
CA2729011A1 (en) * 2007-07-19 2009-01-22 Novavax, Inc. Varicella zoster virus-virus like particles (vlps) and antigens
EP2670443A4 (en) * 2011-01-31 2015-10-14 Univ Pennsylvania Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
KR101723605B1 (en) * 2014-10-21 2017-04-07 진원생명과학 주식회사 Dna vaccine composition for preventing and treating herpes zoster and method of activating t-cell to vzv antizen by using the same
WO2018097642A1 (en) * 2016-11-25 2018-05-31 재단법인 목암생명과학연구소 Varicella zoster virus vaccine
KR102028463B1 (en) * 2016-11-25 2019-10-04 재단법인 목암생명과학연구소 Varicella Zoster Virus Vaccines
CN112142828B (en) * 2019-06-28 2022-02-01 怡道生物科技(苏州)有限公司 gE gene and vector for expressing the gene
EP4074335A4 (en) * 2019-12-13 2024-09-04 Grand Theravac Life Science Nanjing Co Ltd Immunostimulatory composition and use thereof
CN115819616A (en) * 2021-07-28 2023-03-21 江苏瑞科生物技术股份有限公司 Gene recombination VZV fusion protein and preparation method and application thereof
MX2024006407A (en) 2021-11-24 2024-08-19 Flagship Pioneering Innovations Vi Llc Varicella-zoster virus immunogen compositions and their uses.
CN114891830B (en) * 2022-04-02 2024-03-01 武汉博沃生物科技有限公司 Recombinant expression vector based on varicella-zoster virus, recombinant virus and application thereof
WO2024153235A1 (en) * 2023-01-19 2024-07-25 厦门大学 Fusion protein of ge and gi of varicella-zoster virus and use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69017769T2 (en) * 1989-06-27 1995-07-13 Smithkline Beecham Biologicals S.A., Rixensart Links.
GB9226768D0 (en) * 1992-12-23 1993-02-17 Smithkline Beecham Biolog Vaccines
GB9413751D0 (en) * 1994-07-07 1994-08-24 British Bio Technology Immunodominant peptides
CZ289971B6 (en) * 1996-02-09 2002-05-15 Smithkline Beecham Biologicals S. A. Pharmaceutical preparation against product of gene 63 Varicella Zoster

Also Published As

Publication number Publication date
GB9901254D0 (en) 1999-03-10
AU2292600A (en) 2000-08-07
CO5241364A1 (en) 2003-01-31
WO2000043527A1 (en) 2000-07-27

Similar Documents

Publication Publication Date Title
AR027484A1 (en) USEFUL FUSION PROTEIN IN THE TREATMENT OR PREVENTION OF ZOSTER HERPES AND IN THE PREVENTION OR TREATMENT OF VARICEL, DNA AND RNA INFECTIONS QUECODIFY SUCH PROTEIN; EXPRESSION VECTORS AND RECOMBINANT MICROORGANISMS THAT INCLUDE SUCH DNA OR RNA; VACCINE COMPOSITIONS THAT INCLUDE DICH
ECSP093601A (en) PROTEINS DERIVED FROM THE WHITE SPOT SYNDROME VIRUS AND ITS USES
DK0587780T4 (en) Infectious agent that causes Mystery Swine Disease, vaccine preparations and diagnostic kits
ES2140418T3 (en) CHEMICAL FLAVIVIRUS AND / OR RESTRICTED GROWTH FLAVIVIRUS.
ATE270342T1 (en) ENDOSOMOLYTIC PARTICLES
IL150571A0 (en) Novel chimeric proteins and methods for using the same
ES2054601T3 (en) PROTEIN WITH CYTOKINE TYPE ACTIVITY, RECOMBINANT DNA CODE FOR THIS PROTEIN, CELLS AND TRANSFORMED MICROORGANISMS.
DK1349944T3 (en) Latency-associated peptide of TGF-beta to confer latency to pharmaceutically active proteins
EA200400962A1 (en) POLYALKYLENE GLYCOL WITH RESIDUAL FOR CONJUGATION OF BIOLOGICALLY ACTIVE CONNECTION
BR0107703A (en) Recombinant flaviviruses and processes for their use
ES2146214T3 (en) VACCINES FOR ACTINOBACILLUS PLEUROPNEUMONIAE.
AR029644A1 (en) ISOLATED PROTEIN, ISOLATED POLINUCLEOTIDE, TRANSGENIC GUEST CELL, METHOD FOR CONTROLLING A NON-MAMMAL PEST, BIOLOGICALLY PURE CULTURE
FI860445A0 (en) PARVOVIRUS VACCIN FOER HUND.
ES2137310T3 (en) VACCINE AGAINST STREPTOCOCCUS SUIS INFECTION.
BR9803960A (en) D-sorbitol dehydrogenase gene.
AR042968A1 (en) ANTI-DENGUE VIRUS ANTIBODIES COMPOSITIONS METHODS AND USES
BR112022026248A2 (en) CYTOKINE CONJUGATES
AR005750A1 (en) PHARMACEUTICAL COMPOSITION TO TREAT OR PREVENT ZOSTER INFECTIONS IN PERSONS INFECTED WITH THE VARICELA ZOSTER VIRUS AND PROCEDURE FOR PREPARING SUCH COMPOSITION
DK1417222T3 (en) Isolated polypeptides based on the neutralizing epitope of the p17 protein from HIV suitable for vaccines as well as neutralizing anti-p17 antibodies that specifically recognize said neutralizing epitope
DK0918865T3 (en) Immunologically active proteins of Borrelia burgdorferi, therefore coding nucleic acids and their use in test kits and as vaccines
PE20001287A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DNA FRAGMENTS ENCODING AN ANTIGENIC PROTEIN WITH ANTITUMORAL EFFECT
AR028713A1 (en) IMMUNIZATION OF MILK-PRODUCED LIVESTOCK WITH CHEMERIC GAPC PROTEINS AGAINST STREPTOCOCCUS INFECTIONS
ES2136062T3 (en) PLASMID PCTD ISOLATED FROM CHLAMYDIA TRACHOMATIS SEROTYPE D, GENES AND PROTEINS CODED BY THE SAME; RECOMBINANT PLASMIDS FOR THE EXPRESSION OF SUCH GENES IN HETEROLOGICAL SYSTEMS AS RECOMBINANT FUSION PROTEINS, PREPARATION OF SUCH RECOMBINANT PROTEINS AND ...
WO2001055353A3 (en) Recombinant attenuation of prrsv
BR0010222A (en) Viral Expression Vectors